REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY trial meets primary outcome, improving survival in hospitalized COVID-19 patients lacking an immune response to SARS-CoV-2.
Share:
- UK RECOVERY investigators found REGEN-COV reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response (primary outcome for the primary analysis population)
- First trial to demonstrate that any antibody treatment improved survival in patients hospitalized with COVID-19
- Regeneron will share new data with regulatory authorities immediately and request that the US Emergency Use Authorization be expanded to include appropriate hospitalized patients
Read the full press release here.
Source : Regeneron Pharmaceuticals, Inc.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.